Introduction {#s01}
============

Gastric cancer (GC) is one of the most commonly observed digestive malignant tumors, worldwide, and is associated with a high mortality ([@b1]). In China, more than 410,000 new GC cases and 290,000 GC-associated deaths are observed each year ([@b2]). The most effective treatment for curable GC is surgical resection. However, GC shows a strong tendency for lymph node (LN) involvement and local spread. Therefore, lymphadenectomy has crucially important clinical significance in such settings, and the extent of lymphadenectomy also directly influences survival outcomes. Subtotal gastrectomy with D2 lymphadenectomy is considered the standard treatment procedure for curative advanced GC located in the antrum ([@b3]-[@b5]). However, it is controversial whether D2-plus lymphadenectomy including dissection of the posterior (No. 8p, No. 12b/p, No. 13, and No. 14v), and para-aortic (No. 16a2, and No. 16b1) LNs can contribute to improving patient outcomes.

The Japan Clinical Oncology Group (JCOG) 9501 trial ([@b6]) showed no survival benefit in GC patients after D2-plus para-aortic LN dissection compared with after D2 lymphadenectomy. Meanwhile, clinical trials conducted in Poland and eastern Asia ([@b7],[@b8]) also showed that D2-plus lymphadenectomy did not significantly improve survival in GC patients. The No. 14v LN station, the inclusion in D2 lymphadenectomy of which was controversial in Japan, is now not included in D2 lymphadenectomy for gastric antral carcinoma, according to the latest treatment guidelines ([@b9]). However, gastric antral carcinoma has a strong tendency to invade the duodenal region LN stations, including No. 5, No. 6, No. 12, No. 13, and No. 14v ([@b10]). A recent investigation showed that the dissection of the No. 14v LN could improve the 5-year survival rates in patients with advanced gastric antral carcinoma ([@b11]). In addition, several observational studies have reported that the dissection of the No. 8p, No. 12p, No. 13, No. 14v and No. 16 LN stations may be significantly correlated with better prognoses in advanced GC after curative surgery ([@b12]-[@b14]). Therefore, the authors of the above-mentioned reports suggest it should be reconsidered whether D2 lymphadenectomy is the optimal extent for advanced gastric antral carcinoma. Accordingly, we aimed to investigate the prognostic impact of D2-plus lymphadenectomy including dissection of the posterior (No. 8p, No. 12b/p, No. 13, No. 14v), and para-aortic (No. 16a2, and No. 16b1) LNs to elucidate the optimal extent of lymphadenectomy for patients with advanced gastric antral carcinoma and to analyze the possible risk factors for LN metastases beyond the extent of D2 lymphadenectomy.

. Materials and methods {#s02}
=======================

Patients {#s02.01}
--------

We retrospectively reviewed 1,744 patients with advanced GC who had undergone R0 distal gastrectomy with D2 or D2-plus lymphadenectomy at Tianjin Medical University Cancer Institute & Hospital, between January 2003 and December 2011. Patient data were retrieved retrospectively from the patients' hospital records. Eligibility criteria included: 1) proven primary carcinoma located in the antrum, histologically; 2) T2 or more advanced stage; 3) curative gastrectomy with pathologically negative resection margins (R0 resection); 4) D2 or D2-plus lymphadenectomy; and 5) remaining alive at the initial hospital stay and the first postoperative month. The exclusion criteria were: 1) history of gastrectomy or other malignancies; 2) history of neoadjuvant chemotherapy; 3) distant metastases or peritoneal dissemination; 4) loss of follow-up; or 5) death due to other diseases or accidents. Ultimately, 203 patients in total were enrolled in this study. Among these patients, 101 patients underwent D2 lymphadenectomy (D2 group) and 102 underwent D2-plus lymphadenectomy (D2-plus group).

The study was approved by the Ethics Committee of Tianjin Medical University Cancer Institute & Hospital. All patients provided written informed consent before any enrolling procedures were initiated.

. Surgical management {#s02.02}
---------------------

Curative gastrectomy with lymphadenectomy was performed in all patients. Curative resection was defined as the complete absence of grossly visible tumor tissue and pathologically negative resection margins. Primary tumors were resected *en bloc* with D2 lymphadenectomy, according to Japanese Gastric Cancer Association guidelines ([@b15]). We carried out more radical surgery in some cases including dissection of the posterior LN stations along the hepatic artery (No. 8p), the hepato-duodenal ligament (No. 12b/p), the pancreatic head (No. 13) and the superior mesenteric vein (No. 14v), because of the stronger tendency to invade the duodenal region LN stations. The dissection of these LNs additionally depended on intraoperative examination (invasion beyond the muscolaris propria or suspicious LN metastases), based on surgeon decision. The additional para-aortic LNs (No. 16a2, and No. 16b1) were dissected in some patients, with positive para-aortic nodes on preoperative CT scan or intraoperative examination ([@b16]). D2-plus lymphadenectomy was defined as the D2 lymphadenectomy with any LN station dissection beyond D2 region. The chosen surgical procedures were based mainly on Japanese GC treatment guideline ([@b15]).

. Follow-up {#s02.03}
-----------

After curative surgery for GC, all patients were followed up every 3 or 6 months for 2 years, and annually, thereafter, until death. The median follow-up time for the entire cohort was 44 (range, 4−138) months. The follow-up of all the patients in this study was completed in December 2015. At every visit, patients underwent ultrasonography, computed tomography, chest radiography, and endoscopy. Overall survival (OS) served as the primary end-point, and was defined as the time interval between the date of surgery and the date of either death as a result of GC or the last follow-up. During the follow-up period, 150 patients (74.9%) died.

. Propensity score matching (PSM) {#s02.04}
---------------------------------

To overcome possible selection bias between the D2 and D2-plus groups, we performed one-to-one matching using PSM ([@b17],[@b18]). The propensity score, defined as the conditional probability of patients being treated given the covariates, can be used to balance the covariates in two groups and therefore reduce such bias ([@b19],[@b20]). It has also been reported that potential confounding variables that are unrelated to the exposure but related to the outcome should be included in the propensity score model, and that this will decrease the variance of an estimated exposure effect without increasing the bias ([@b21]). The propensity scores were estimated by using a nonparsimonious multiple logistic regression model. Accordingly, in our study, which aimed to obtain more reliable results, the following covariates were selected for the calculation of the propensity score: sex, age, tumor size, Lauren type, pT stage, pN stage, pTNM stage. Eventually, 38 pairs of exact matching and 14 pairs of nearest neighbor matching patients were included after matching.

. Therapeutic value of LN dissection {#s02.05}
------------------------------------

The therapeutic value of each LN dissection was determined by a therapeutic value index (TVI), which was calculated by multiplication of the frequency of metastasis to the station and the 5-year survival rate of patients with metastasis to that station ([@b22]). The frequency of metastasis to each station was calculated by dividing the number of patients with metastasis at that station by the number in whom the station was dissected. The cumulative 5-year survival rate of patients with LN metastasis was calculated for each nodal station by the life-table method, irrespective of metastasis to other LN stations ([@b22]).

. Statistical analysis {#s02.06}
----------------------

The χ^2^ or Fisher's exact test used for categorical variables, and a *t* test was used for continuous variables. Factors that showed significant difference in the univariate analysis (P\<0.05) were included in the multivariate analysis. Multivariate analysis was performed using a logistic regression model for the evaluation of the predictive risk factors. OS was determined using the Kaplan-Meier method, and a log-rank test was used to evaluate significance. Multivariate analyses of OS were performed to calculate the hazard ratios (HRs) and 95% confidence interval (95% CI) through the Cox regression model. In all the other statistical analyses, significance was defined as P\<0.05 (two-sided). All statistical analyses were performed using the statistical analysis program package IBM SPSS Statistics (Version 24.0; IBM Corp., New York, USA).

. Results {#s03}
=========

Clinical characteristics before and after PSM {#s03.01}
---------------------------------------------

The clinical characteristics of GC patients in the D2 and D2-plus groups are listed in *[Table 1](#Table1){ref-type="table"}*. A total of 101 (49.8%) and 102 (50.2%) patients were assigned to the D2 group and D2-plus group, respectively. Before matching, we observed some difference between the groups in terms of sex (P=0.033), Lauren type (P=0.061), and pN stage (P=0.084). After PSM (*[Table 1](#Table1){ref-type="table"}*), 52 pairs of patients were enrolled. The strength of the selective bias between the two groups was reduced after matching, including sex (P=0.836), Lauren type (P=0.807), and pN stage (P=0.877). This implicated that the confounding factors were balanced. In addition, the number of total LNs dissected (before P=0.266, after P=0.604), the proportion of LNs metastasis (before P=0.311, after P=0.406) and the number of LNs metastasis in the D2 lymphadenectomy region (before P=0.635, after P=0.511) showed no significant difference between D2 and D2-plus group both before and after PSM, which showed good comparability of two groups (*[Table 1](#Table1){ref-type="table"}*).

###### Clinical characteristics of patients in D2 and D2-plus groups before and after PSM

  Characteristics                                                                          Entire cohort   P           PSM       P                       
  ---------------------------------------------------------------------------------------- --------------- ----------- --------- ----------- ----------- ---------
  Sex                                                                                                                  0.033                             0.836
  　Male                                                                                   71              57                    35          34          
  　Female                                                                                 30              45                    17          18          
  Age (year)                                                                                                           0.413                             0.502
  　≤65                                                                                    69              75                    40          37          
  　\>65                                                                                   32              27                    12          15          
  Tumor size (cm)                                                                                                      0.623                             0.844
  　≤4.0                                                                                   49              53                    26          25          
  　\>4.0                                                                                  52              49                    26          27          
  Lauren type                                                                                                          0.061\*                           0.807
  　Intestinal                                                                             28              20                    10          11          
  　Diffuse                                                                                72              77                    42          41          
  　Mixed                                                                                  1               5                     50          50          
  pT stage                                                                                                             0.790                             1.000
  　T2                                                                                     20              19                    59          59          
  　T3                                                                                     5               7                     51          51          
  　T4a                                                                                    74              72                    41          41          
  　T4b                                                                                    2               4                     51          51          
  pN stage                                                                                                             0.084                             0.877\*
  　N0                                                                                     50              37                    24          25          
  　N1                                                                                     13              26                    10          12          
  　N2                                                                                     21              16                    7           4           
  　N3a                                                                                    10              17                    8           9           
  　N3b                                                                                    7               7                     3           2           
  pTNM stage                                                                                                           0.600                             0.847\*
  　IA                                                                                     0               0                     0           0           
  　IB                                                                                     16              12                    7           8           
  　IIA                                                                                    6               6                     2           0           
  　IIB                                                                                    29              25                    16          19          
  　IIIA                                                                                   33              33                    16          14          
  　IIIB                                                                                   10              19                    8           9           
  　IIIC                                                                                   7               7                     3           2           
  Number of total LNs dissected                                                                                        0.266                             0.604
  　\<16                                                                                   22              16                    10          8           
  　≥16                                                                                    79              86                    42          44          
  Proportion of LNs metastasis                                                                                         0.311                             0.406
  　0                                                                                      49              37                    24          25          
  　\<10%                                                                                  14              17                    9           9           
  　10%−40%                                                                                26              36                    11          15          
  　\>40%                                                                                  12              12                    8           3           
  Extent of LNs metastasis                                                                                             0.140                             0.512
  　Peri-gastric                                                                           75              66                    39          36          
  　Extra-gastric                                                                          26              36                    13          16          
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. Dissection range and distribution of LN metastases beyond the extent of D2 lymphadenectomy {#s03.02}
--------------------------------------------------------------------------------------------

*[Supplementary Figure S1](#FigureS1){ref-type="fig"}* shows the regions of D2-plus lymphadenectomy, and the distribution of LN metastasis beyond the extent of D2 lymphadenectomy in patients with advanced gastric antral carcinoma. In 102 patients who underwent D2-plus lymphadenectomy, the No. 12b (54/102), No. 13 (39/102), No. 12p (35/102) and No. 14v (25/102) LN stations were the most frequently dissected sites. Finally, 21 (20.59%) of the 102 patients were pathologically identified as having LN metastases beyond the extent of D2 lymphadenectomy. The highest LN metastasis proportions beyond the extent of D2 lymphadenectomy contained the No. 8p (28.6%), No. 14v (20.0%) and No. 12p (17.1%) stations.

![Distribution and metastasis rate of each LN station. No. 8p, the hepatic artery; No. 12b/p, the hepato-duodenal ligament; No. 13, the pancreatic head; No. 14v, the superior mesenteric vein; No. 16a2 and No. 16b1, para-aortic LNs. LN, lymph node.](cjcr-32-1-51-S1){#FigureS1}

. Correlation analysis of risk factors for LN metastases beyond the extent of D2 lymphadenectomy {#s03.03}
------------------------------------------------------------------------------------------------

The univariate analysis showed that LN metastases beyond the extent of D2 lymphadenectomy were significantly correlated with age (P=0.048), pN stage (P\<0.001), proportion of LNs metastasis (P\<0.001), and extent of LNs metastasis (P\<0.001) (*[Table 2](#Table2){ref-type="table"}*). These factors which have the significant difference (P\<0.05) in the univariate analysis were included in the multivariate analysis. We adopted logistics regression method with forward step procedures in the multivariate analysis. pN stage \[odds ratio (OR), 2.533; 95% CI, 1.368−4.691; P=0.003\] and extent of LNs metastasis (OR, 5.965; 95% CI, 1.335−26.650; P=0.019) were identified as independent risk factors for LN metastases beyond the extent of D2 lymphadenectomy in patients with advanced gastric antral carcinoma (*[Table 2](#Table2){ref-type="table"}*).

###### Correlation analysis of risk factors for LN metastasis beyond the extent of D2 lymphadenectomy (N=102)

  Characteristics                 Univariate analysis        Multivariate analysis                                         
  ------------------------------- --------------------- ---- ----------------------- ----------- -- ------- -------------- -------
  Sex                                                                                0.896                                 
  　Male                          57                    12   45                                                            
  　Female                        45                    9    36                                                            
  Age (year)                                                                         0.048                                 
  　≤65                           75                    19   56                                                            
  　\>65                          27                    2    25                                                            
  Tumor size (cm)                                                                    0.966                                 
  　≤4.0                          53                    11   42                                                            
  　\>4.0                         49                    10   39                                                            
  Lauren type                                                                        1.000\*                               
  　Intestinal                    20                    4    16                                                            
  　Diffuse                       77                    16   61                                                            
  　Mixed                         5                     1    4                                                             
  pT stage                                                                           0.194\*                               
  　T2                            19                    1    18                                                            
  　T3                            7                     2    5                                                             
  　T4a                           72                    17   55                                                            
  　T4b                           4                     1    3                                                             
  pN stage                                                                           \<0.001\*      2.533   1.368−4.691    0.003
  　N0                            37                    0    37                                                            
  　N1                            25                    3    22                                                            
  　N2                            16                    5    11                                                            
  　N3a                           17                    7    10                                                            
  　N3b                           7                     6    1                                                             
  Number of total LNs dissected                                                      0.593\*\*                             
  　\<16                          16                    2    14                                                            
  　≥16                           86                    19   67                                                            
  Proportion of LNs metastasis                                                       \<0.001\*                             
  　0                             37                    0    37                                                            
  　\<10%                         17                    4    13                                                            
  　10%−40%                       36                    11   25                                                            
  　\>40%                         12                    6    6                                                             
  Extent of LNs metastasis                                                           \<0.001        5.965   1.335−26.650   0.019
  　Peri-gastric                  66                    3    63                                                            
  　Extra-gastric                 36                    18   18                                                            

. Survival analysis before and after PSM {#s03.04}
----------------------------------------

The prognostic value of D2-plus lymphadenectomy in gastric antral carcinoma was determined. During the follow-up, 150 patients died and 53 patients remained alive. Kaplan-Meier analyses showed no significant difference in terms of prognosis between the D2 and D2-plus groups (P=0.417) before PSM. After PSM, 104 patients were enrolled in this study. The median survival times of patients with D2 lymphadenectomy and those with D2-plus lymphadenectomy were 34±3 months and 53±6 months, respectively. Kaplan-Meier analysis showed that OS of patients in the D2-plus group was significantly superior to that of those in the D2 group (P=0.030) (*[Figure 1](#Figure1){ref-type="fig"}*). To confirm the survival factors, we performed univariate analysis and Cox regression analysis (*[Table 3](#Table3){ref-type="table"}*). In the univariate survival analysis, tumor size (P=0.004), pT stage (P=0.002), pN stage (P\<0.001), and D2-plus*vs.* D2 LN dissection (P=0.039) were confirmed as prognostic factors for OS, whereas other clinicopathological characteristics, such as sex, age, and Lauren type had no prognostic significance for OS. The results of the Cox regression analysis were showed in *[Table 3](#Table3){ref-type="table"}*, *[Figure 2](#Figure2){ref-type="fig"}*. These results showed that more advanced T stage (pT4a *vs*. pT2: HR, 2.791; 95% CI, 1.248−6.244; P=0.012; and pT4b*vs.* pT2: HR, 12.714; 95% CI, 2.462−65.644; P=0.002) and more advanced pN stage (pN3a*vs*. pN0: HR, 2.473; 95% CI, 1.316−4.646; P=0.005; and pN3b*vs.* pN0: HR, 9.379; 95% CI, 3.332−26.395; P\<0.001) were significantly associated with poor prognoses, and that D2-plus lymphadenectomy (HR, 0.516; 95% CI, 0.323−0.825; P=0.006) should provide superior survival.

![Kaplan-Meier curves for overall survival before (A) (P=0.417) and after (B) (P=0.030) propensity score matching.](cjcr-32-1-51-1){#Figure1}

![Forest plot of pT stage, pN stage and extent of lymph node (LN) metastases in advanced gastric antral carcinoma after propensity score matching. In pT stage, other stages *vs.* pT2 stage; in pN stage, other stages *vs.* pN0 stage; in extent of LN metastases, D2-plus lymphadenectomy *vs.* D2 lymphadenectomy. OR, odds ratio; 95% CI, 95% confidence interval.](cjcr-32-1-51-2){#Figure2}

###### Survival analysis of prognostic factors in patients with distal GC after matching

  Predictors                               Univariate analysis              Cox regression analysis                           
  ---------------------------------------- ---------------------- --------- ------------------------- ----------------------- ---------
  Time of surgery (year)                                          0.469                                                       
  　2006−2008*vs.* 2003−2005               1.246 (0.738−2.104)    0.410                                                       
  　2009−2011*vs*. 2003−2005               0.893 (0.504−1.583)    0.699                                                       
  Sex (female *vs.* male)                  1.113 (0.701−1.767)    0.649                                                       
  Age (\>65*vs*. ≤65) (year)               1.245 (0.765−2.026)    0.377                                                       
  Tumor size (\>4*vs.* ≤4) (cm)            1.940 (1.236−3.044)    0.004                                                       
  Lauren type (diffuse *vs.* intestinal)   1.226 (0.699−2.153)    0.477                                                       
  pT stage                                                        0.002                                                       0.011
  　pT3 *vs.* pT2                          3.464 (0.718−16.717)   0.122                               4.026 (0.786−20.613)    0.095
  　pT4a *vs.* pT2                         3.158 (1.447−6.889)    0.004                               2.791 (1.248−6.244)     0.012
  　pT4b *vs.* pT2                         7.830 (1.586−38.662)   0.012                               12.714 (2.462−65.664)   0.002
  pN stage                                                        \<0.001                                                     \<0.001
  　pN1 *vs.* pN0                          1.575 (0.883−2.812)    0.124                               1.471 (0.808−2.679)     0.206
  　pN2 *vs*. pN0                          1.811 (0.833−3.939)    0.134                               2.164 (0.979−4.784)     0.057
  　pN3a *vs*. pN0                         2.509 (1.370−4.595)    0.003                               2.473 (1.316−4.646)     0.005
  　pN3b *vs.* pN0                         8.080 (3.003−21.739)   \<0.001                             9.379 (3.332−26.395)    \<0.001
  D2-plus *vs.* D2 LN dissection           0.625 (0.400−0.977)    0.039                               0.516 (0.323−0.825)     0.006

. TVI {#s03.05}
-----

We next used TVI to evaluate the survival benefit of each LN in the D2-plus lymphadenectomy region. The TVI values were 7.1 for No. 8p, 5.7 for No. 12p, 5.1 for No. 13, 7.1 for No. 16a2 and 7.1 for No. 16b1, respectively, which were better than some LNs station in D2 lymphadenectomy region, such as No. 7 (3.4), No. 8a (5.0) and No. 9 (3.4) (*[Table 4](#Table4){ref-type="table"}*). The 5-year OS information of each LN station was also available in *[Table 4](#Table4){ref-type="table"}*.

###### TVI of each LNs station in D2-plus lymphadenectomy region

  LN station   Proportion of LN metastasis \[% (n/N)\]   5-year OS (%)   TVI
  ------------ ----------------------------------------- --------------- -----
  No. 1        10.06 (18/179)                            44.4            4.5
  No. 3        30.43 (56/184)                            23.2            7.1
  No. 4sb      15.98 (27/169)                            22.2            3.5
  No. 4d       2.52 (4/159)                              25.0            0.6
  No. 5        12.50 (23/184)                            26.1            3.3
  No. 6        34.30 (59/172)                            27.1            9.3
  No. 7        17.61 (31/176)                            19.4            3.4
  No. 8a       18.01 (29/161)                            27.5            5.0
  No. 8p       28.57 (4/14)                              25.0            7.1
  No. 9        13.14 (23/175)                            26.1            3.4
  No. 11p      4.47 (8/179)                              0               0
  No. 12a      7.09 (10/141)                             10.0            0.7
  No. 12b      12.96 (7/54)                              13.2            1.7
  N0. 12p      17.14 (6/35)                              33.3            5.7
  No. 13       12.82 (5/39)                              40.0            5.1
  No. 14v      20.00 (5/25)                              20.0            4.0
  No. 16a2     14.29 (2/14)                              50.0            7.1
  No. 16b1     14.29 (2/14)                              50.0            7.1

. Discussion {#s04}
============

LN metastasis has a key role in determining the OS associated with GC. The extent of lymphadenectomy is also of great clinical significance in GC. Subtotal gastrectomy with D2 lymphadenectomy, including dissection of the No. 1, No. 3, No. 4sb, No. 4d, No. 5, No. 6, No. 7, No. 8a, No. 9, No. 11p and No. 12a LN stations, is considered the standard treatment for curable gastric antral carcinoma cases, according to Japanese GC guidelines ([@b5]). Although there has been several researches to investigate the prognostic impacts of D2-plus lymphadenectomy, it has still been controversial whether the D2-plus lymphadenectomy can contribute to improving patients' outcomes, until now. This may be explained by different patients enrolled and methods adopted. We therefore enrolled the patients with advanced gastric antral carcinoma which has a strong tendency to invade the duodenal region LN stations and adopted PSM to reduce the strength of the confounding factors, in order to accurately evaluate the prognostic impacts of D2-plus lymphadenectomy.

In this study, the extent of lymphadenectomy beyond D2 mainly comprised the No. 8p, No. 12b/p, No. 13, No. 14v, No. 16a2, and No. 16b1 LN stations. Based on our results, the highest frequency of metastatic LNs involved the No. 8p (28.6%), No. 14v (20.0%) and No. 12p (17.1%) stations, similar to the findings of previous investigations in China ([@b23]). However, our results are tremendously different from those of an Italian study ([@b24]), in which the metastatic proportions associated with the No. 8p. and No. 12b/p stations were 3.1% and 1.6%, respectively; this may be attributed to differences in the environment and race between the two countries. According to a multicenter study in China that enrolled 8,338 GC patients ([@b25]), and another multicenter Italian study that enrolled 743 GC patients ([@b24]), there are a larger number of GC patients with advanced disease stage (pT4 stage: 54.5% in China *vs.* 44.8% in Italy; pN3 stage: 28.1% in China *vs.* 16.6% in Italy) in China. Thus, metastatic LNs beyond the extent of D2 lymphadenectomy should be carefully detected in China, especially in patients with advanced disease stage.

In the present study, the univariate analysis revealed that the presence of LN metastases beyond the extent of D2 lymphadenectomy was significantly correlated with the age (P=0.048), pN stage (P\<0.001), proportion of LNs metastasis (P\<0.001) and extent of LNs metastasis (P\<0.001). In the multivariate logistic analysis, pN stage and extent of LNs metastasis were identified as independent risk factors. That results indicated patients with more advanced pN stage and more extra-gastric metastatic LNs might have more opportunities of LN metastases beyond the extent of D2 lymphadenectomy in advanced gastric antral carcinoma. Our results also showed the prognostic significance of D2-plus lymphadenectomy. Before PSM, our results failed to show any significant difference with regard to the extent of lymphadenectomy (P=0.417) between the groups. This result was in line with those of several previous studies ([@b6]-[@b8]). To eliminate selection bias, we adopted the PSM method to balance the confounding factors between the D2 and D2-plus groups. After PSM, patients in the D2-plus group had a significantly superior OS than those in the D2 group (P=0.030). Cox regression analysis further confirmed that D2-plus lymphadenectomy was an independent factor associated with prognosis in advanced gastric antral carcinoma. Recently, de Manzoni *et al.* ([@b12]) reported that D2-plus lymphadenectomy, which includes the removal of the No. 12p, No. 13, No. 14v and No. 16 LN stations, was associated with a lower risk of recurrence, and may provide better local control in GC. Kumagai *et al.* ([@b10]) also reported that the dissection of the No. 12b, No. 13, No. 14v, No. 16a2 and No. 16b1 LN stations in potentially curative gastrectomy for patients with gastric antral carcinoma can yield survival benefits. These results are almost similar to those of our study. According to *[Figure 1](#Figure1){ref-type="fig"}*, the prognosis between D2 and D2-plus groups was the same before the matching, but was different after the matching. This result meant that D2-plus lymphadenectomy should be performed for some sort of high-risk patients. Furthermore, we found that sex (P=0.033), Lauren type (P=0.061), and pN stage (P=0.084) were predominantly responsible for the selective bias between the D2 group and D2-plus group. In the entire cohort of GC patients, the D2-plus group tended to enroll a larger number of female patients with mixed-diffuse histology or pN3 stage disease. It has been reported that, in female patients, GC is significantly correlated with diffuse histology and mixed-diffuse histology ([@b26],[@b27]) and pN3 stage is associated with poor survival ([@b28]-[@b31]). This may explain why the above-mentioned studies failed to elucidate the survival benefit of D2-plus lymphadenectomy in patients with gastric antral carcinoma. D2-plus lymphadenectomy may provide survival benefits especially in gastric antral carcinoma patients with diffuse histology or advanced pN stage disease. The results of previous studies ([@b32],[@b33]) also support this result. Accordingly, we considered that D2-plus lymphadenectomy could improve survival in some cases with advanced gastric antral carcinoma, especially for patients with diffuse histology or advanced pN stage.

TVI was used to evaluate the survival benefit of dissecting each LN station in the D2 lymphadenectomy region. The results of TVI showed the possible survival benefit of dissecting No. 8p, No. 12p, No. 13, No. 16a2 and No. 16b1 LNs in a D2-plus gastrectomy for advanced gastric antral carcinoma. The high incidence of LN metastasis for No. 8p (28.57%) and high 5-year OS for No. 16a2 (50.00%) and No.16b1 (50.00%) might result in a relatively high TVI for No. 8p station (7.1), No. 16a2 (7.1) and No. 16b1 (7.1). Kumagai's study ([@b10]) also confirmed the possible survival benefit of dissecting No. 13, 16a2 and 16b1 and got the different results for the No. 8p and No. 12p LNs station. Notably, the high TVI in this study may be due to the small number of patients who have that LN station metastasis in this study. Therefore, a study with large sample size is needed further.

With improvements in the surgical techniques used currently, including laparoscopy and da Vinci Robot, the safety of surgery is on the rise. Contrary to some previous studies ([@b34],[@b35]), recent studies ([@b36],[@b37]) have shown that D2-plus lymphadenectomy is safe, and does not increase the rate of major surgical complications. At present, our results showed that D2-plus lymphadenectomy, when performed by specialized experienced surgeons, may yield better survival. We believe that, with the use of more convenient and efficient devices, D2-plus lymphadenectomy is completely feasible.

This study has several limitations. First, in this study, the endpoint was OS; we did not investigate disease-free survival. Second, our study had a single-center retrospective design. Third, our study did not have a large sample size. Thus, there is a need for a multicenter randomized clinical trial with a larger sample size to confirm our findings.

. Conclusions {#s05}
=============

D2-plus lymphadenectomy should be performed to improve survival in some cases with gastric antral carcinoma, especially for patients with diffuse histology or advanced pN stage. That survival benefits may get from the dissection of No. 8p, No. 12p, No. 13, No. 16a2 and No. 16b1 LN stations. In addition, there is also a need for a multicenter randomized clinical trial with a larger sample size to confirm our findings.
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